Pliant Therapeutics Stock Filter Stocks by Fundamentals
| PLRX Stock | USD 13.46 0.48 3.70% |
Pliant Therapeutics fundamentals help investors to digest information that contributes to Pliant Therapeutics' financial success or failures. It also enables traders to predict the movement of Pliant Stock. The fundamental analysis module provides a way to measure Pliant Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pliant Therapeutics stock.
Pliant | Shares Owned by Institutions |
Pliant Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pliant Therapeutics from analyzing Pliant Therapeutics' financial statements. These drivers represent accounts that assess Pliant Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pliant Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 757.2M | 807.8M | 483.9M | 812.2M | 1.1B | 1.1B | |
| Enterprise Value | 671.9M | 757.2M | 439.5M | 794.3M | 1.0B | 1.1B |
Pliant Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pliant Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pliant Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Pliant Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Pliant Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pliant Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pliant Therapeutics' value.| Shares | Polar Capital Holdings Plc | 2024-06-30 | 2 M | Deutsche Bank Ag | 2024-06-30 | 1.5 M | State Street Corp | 2024-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Franklin Resources Inc | 2024-09-30 | 1 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 833.2 K | Deep Track Capital, Lp | 2024-09-30 | 6 M | Blackrock Inc | 2024-06-30 | 5 M |
Pliant Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 445.58 M | ||||
| Shares Outstanding | 60.85 M | ||||
| Shares Owned By Insiders | 2.85 % | ||||
| Shares Owned By Institutions | 97.15 % | ||||
| Number Of Shares Shorted | 7.22 M | ||||
| Price To Book | 2.28 X | ||||
| Price To Sales | 3,050 X | ||||
| Revenue | 1.58 M | ||||
| Gross Profit | 9.69 M | ||||
| EBITDA | (158.23 M) | ||||
| Net Income | (161.34 M) | ||||
| Cash And Equivalents | 163.6 M | ||||
| Cash Per Share | 3.36 X | ||||
| Total Debt | 11.37 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.69 X | ||||
| Book Value Per Share | 5.68 X | ||||
| Cash Flow From Operations | (116.36 M) | ||||
| Short Ratio | 17.04 X | ||||
| Earnings Per Share | (3.35) X | ||||
| Target Price | 40.18 | ||||
| Number Of Employees | 166 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 789.88 M | ||||
| Total Asset | 512.15 M | ||||
| Retained Earnings | (499.75 M) | ||||
| Working Capital | 476.98 M | ||||
| Net Asset | 512.15 M |
About Pliant Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pliant Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.